WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|7|602-607

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.7, 2015-07, pp. : 602-607

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of cellular and humoral response against WT1 protein vaccination in mice

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 9, 2015-09 ,pp. : E193-E194

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high‐risk subgroup using WT1 expression in association with NPM1 and FLT3‐ITD mutations

By  

GENES, CHROMOSOMES AND CANCER, Vol. 54, Iss. 8, 2015-08 ,pp. : 489-499

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dicentric chromosomes and 20q11.2 amplification in MDS/AML with apparent monosomy 20

By  

Cytogenetic and Genome Research, Vol. 119, Iss. 3-4, 2008-02 ,pp. : 211-220

Karger

Access to resources Recommend Favorite

Valproic Acid and All-Trans Retinoic Acid: Meta-Analysis of a Palliative Treatment Regimen in AML and MDS Patients

By  

Oncology Research and Treatment, Vol. 31, Iss. 11, 2008-10 ,pp. : 629-633

Karger

Access to resources Recommend Favorite

A vaccine for leukemia: one step closer? Cure-oriented WT1 peptide vaccination therapy is being developed

By Oka Yoshihiro  

Clinical Investigation, Vol. 3, Iss. 5, 2013-05 ,pp. : 421-424

Future Science

Access to resources Recommend Favorite